Spyre Therapeutics, Inc.
For the period ended Sep 8, 2026. Filed Sep 8, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Sep 8, 2026 · Filed Sep 8, 2026
Use the contents to explore the available documents and sections.
Contents
Next Steps
Clinical proof-of-concept across all three inflammatory bowel disease (“IBD”) programs strengthens the biological rationale for Spyre’s combination strategy and sets the stage for Part B of the SKYLINE trial, which is actively enrolling. Part B includes two dose levels of each monotherapy as well as three high-dose combination arms (SPY120, SPY130, and SPY230). Topline induction data from Part B are expected in 2027.
The Company remains at the forefront of evaluating potential first- and best-in-class monotherapies and combinations in immunology and inflammation (“I&I”), with multiple expected topline readouts over the next 12-18 months:
| Trial | Indication | Asset(s) | Expected timing |
|---|---|---|---|
| SKYWAY | Psoriatic Arthritis (“PsA”), Axial Spondyloarthritis (“axSpA”) | SPY072 | 4Q 2026 |
| SKYLINE Part B | UC | SPY001, SPY002, SPY003, SPY120, SPY130, SPY230 | 2027 |
| SKYLIGHT | Hidradenitis Suppurativa (“HS”) | SPY072 + IL-17A/F | Late 2027 or early 2028 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.